Statement on Vaccines Roll-out

Click the link to read the details... AIPSN  urges:  The Union Government issue special protocols for Covaxin administration in “clinical trial mode,” including obtaining informed consent or refusal of recipients and ensuring compliance with all CDSCO/SEC approval conditions;  CDSCO and ICMR to ensure that all clinical trials conform to necessary ethical, scientific and technical standards;  All State Governments take a hard decision on whether to deploy Covaxin widely, or whether to strictly conform to CDSCO/SEC conditions of limited “trial mode” deployment;  All doses of Covaxin distributed to States so far be held in stock by them and not administered till greater clarity is given by the Government or till CDSCO/SEC approval conditions are amended based on efficacy data from Bharat Biotech-ICMR as promised.

On Hasty Regulatory Approvals in India for Covid-19 Vaccines

India’s regulatory authority for medical products, the Central Drug Standards Control Organization (CDSCO), gave  “restricted emergency approval” on 2nd January 2020 for two Covid-19 Vaccines, namely Serum Institute of India (SII)’s “Covishield” being manufactured in India under technology transfer from Oxford University-Astra Zeneca, and the indigenous “Covaxin” developed by Bharat Biotech in collaboration with ICMR/National Institute of Virology...click link to read more.... AIPSN calls for: a)Re-consideration of approval for Covaxin till efficacy data is available or, at least, strict adherence to conditions specified in the CDSCO order implying no roll-out of Covaxin for mass vaccination. b) Phase-III efficacy trials for both vaccines continue without extraneous pressure and the data published at the earliest. c) No vaccine or Covid-19 related drug be released for commercial use in the private sector until regular approval as per protocols (as distinct from emergency use authorization) are obtained.

Stop Monopoly Publishers Efforts To Deny Public Access to Scientific Publications

click link to see English and Kannada version pdf of statement... Three major academic publishers—Elsevier Ltd., Wiley India Pvt. Ltd., American Chemical Society— have filed a petition in Delhi High Court asking for dynamic blocking of Sci-Hub and Libgen in India. SciHub is the first site to allow mass and public access to research publications while LibGen allows access to books. These websites help Indian scientists, teachers and students to freely access and download research publications and books even if they are behind paywalls.....For details click the link above.. AIPSN demands that the monopolistic model of access to knowledge be given up and the process of free access to knowledge by the public accepted. AIPSN joins hands in support of those legally fighting these monopoly publishing industries against SciHub and Libgen which are working like the story figure of Robin Hood in making the knowledge commons work by providing the public a way to have their right to accessing knowledge.

Fog over Covid-19 Vaccines in India: All-India Peoples Science Network (AIPSN) Position Paper

The Government of India needs to urgently undertake the following so as to ensure a safe, effective and free universal vaccination programme against Covid-19. Two of the seven demands made in the position paper are highlighted here: 6. Bring out a white paper on the system and related costs for vaccine procurement and delivery, along with details of the expansion of public health infrastructure and human resources that would go with it; 7. Set up a Parliamentary Committee to oversee the implementation of the Covid-19 Vaccination programme in an effective, timely and equitable manner and a broad based Advisory Committee including representation of the scientific community and civil society organizations. For more details click in the link..

Joint Statement on Technical, legal, ethical and implementation concerns regarding Aarogya Setu and other apps introduced during COVID-19 in India by JSA, IFF, FMES and AIPSN

We, the four signatory networks of organizations of public health advocates, experts in digital privacy, science and technology policy advocates and other stakeholders issue this Statement for generating public understanding and for submission to the Government of India (GoI) and concerned Union Ministries – Ministry of Electronics and Information Technology (MEIT), and Ministry of Health and Family Welfare (MoH&FW) – about our deep concerns regarding the Aarogya Setu (AS) and other similar Apps related to the novel Corona virus epidemic. ..Click on the link for more details

AIPSN statement on Vaccines and IPR waiver: India-South Africa Proposal for TRIPS Waiver – Putting People before Profit

India-South Africa Proposal for TRIPS Waiver – Putting People before Profit             As Covid-19 pandemic continues to keep its grip on the globe, countries are facing severe shortages in medical supplies and treatments, with intellectual property rights hindering the timely provisioning of affordable medical products. To address this, India and South Africa have put in a proposal at the Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS), under the World Trade Organisation (WTO), demanding a temporary waiver of certain TRIPS obligations on copyrights and related rights, industrial designs, patents, and the protection of undisclosed information in relation to the prevention, containment or treatment of Covid-19.             ...CLICK link to read more....

Press Note protesting attempt to rename RCGB in unscientific manner

It is learnt that Govt of india has decided to name  the second campus in the name of the RSS founder and ideologue Golwalkar within the campus of existing Rajiv Gandhi Centre for Biotechnology(RGCB) , Trivandram. It is highly condemnable changing the name of a modern research institute in the name of a person who was against the modern technology calling it as western technology.  We urge the Central Government to respect the opinion of Kerala Government and main opposition Party and sentiment of the people of the State. Hence we urge the Govt of india not to change the existing name of the RGCB for the second campus. If there is a need from the administration point of view, it could be that of a reputed scientist in the field of biotechnology.

Statement on post-3rd May 2020 measures against Covid-19 Pandemic

The Central Government has persisted with the Lockdown as the main, if not, the only strategy against the spread of COVID-19.  Underway since March 25th, this lock-down has seen two extensions, one on April 20th and now again on May 3rd.  These one-size-fits-all country-wide lock-downs are badly planned and poorly implemented with measures imposed on the country by the Government using centralizing powers under the Disaster Management Act. The JSA and AIPSN statement reflects on the badly planned and poorly implemented lockdown. F urther, we detail health related and socio-economic measures that the union and state governments must consider. Read the statement for more details

Feedback submitted to MoHFW on draft Health Data Management Policy (HDMP) -with related aspects of the National Digital Health Mission (NDHM)

AIPSN has submitted the response to draft Health Data Management Policy (HDMP) -with related aspects of the National Digital Health Mission (NDHM) for consideration of the MoHFW. 13 points have been raised in the response. AIPSN has insisted that the responses received and discussions be placed transparently in a public accessible website. Click the link to read more